NeuroPace (NPCE) Misses Q4 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to NeuroPace (NPCE) Misses Q4 EPS by 11c

NeuroPace Reports Fourth Quarter & Full Year 2021 Financial Results

March 10, 2022 4:02 PM EST

MOUNTAIN VIEW, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Recent Highlights

Total revenue of $45.2 million for 2021, representing a 10% increase over 2020Initial implant revenue of $33.7 million for 2021, representing a 20% increase over 2020Replacement implant revenue of $11.5 million for 2021, representing a 12% decrease over 2020150 level 4 comprehensive epilepsy centers completed an RNS System implant in 2021, representing a... More